Literature DB >> 788512

Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia.

E T Anderson, L S Young, W L Hewitt.   

Abstract

Of 237 cases of gram-negative rod bacteremia observed at the UCLA Medical Center during a 12 month period, 52 (22 per cent) occurred while the patient was receiving antibiotics which inhibited the infecting organism by disc diffusion tests. One half of the plasma samples available from 42 such patients with "breakthrough" bacteremia had subinhibitory circulating antibiotic levels when cultures were positive. Sepsis documented within 72 hours of initiation of therapy was usually due to antibiotic-sensitive Esch. coli and was associated with inadequate antibiotic levels; the patient was usually treated with a penicillin or cephalosporin. The source of bacteremia was most frequently the urinary tract or the biliary tree. In contrast, sepsis occurring more than 72 hours after the administration of antibiotics was frequently caused by multiple antibiotic-resistant Esch. coli in patients treated with gentamicin in adequate dosage and was associated with leukopenia or undrained purulent collections. Therapy ultimately failed in 20 cases (48 per cent): in early "breakthrough" bacteremia, failure was associated with subinhibitory antibiotic levels, and in late "breakthrough" bacteremias with inadequate drainage or impaired host defenses.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 788512     DOI: 10.1016/0002-9343(76)90328-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  33 in total

1.  Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation.

Authors:  C Triginer; I Izquierdo; R Fernández; J Torrent; S Benito; A Net; F Jane
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.

Authors:  D E Nix; S D Goodwin; C A Peloquin; D L Rotella; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

3.  Breakthrough bacteremia and septic shock due to Streptococcus anginosus resistant to daptomycin in a patient receiving daptomycin therapy.

Authors:  Federico Palacio; James S Lewis; Lee Sadkowski; Kelly Echevarria; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

4.  Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis.

Authors:  Sharon Y Wong; Jong Seok Lee; Hyun Kyung Kwak; Laura E Via; Helena I M Boshoff; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

5.  Prognostic indicators of septicaemia--a two year prospective evaluation.

Authors:  R P Iyer; G K Duckett; T D Brogan; P S Tweedy; T C Sharpe
Journal:  Postgrad Med J       Date:  1987-12       Impact factor: 2.401

6.  Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.

Authors:  Ji-Yong Lee; Cheol-In Kang; Jae-Hoon Ko; Woo Joo Lee; Hye-Ri Seok; Ga Eun Park; Sun Young Cho; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

7.  Amikacin pharmacokinetics in pediatric patients with malignancy.

Authors:  T G Cleary; L K Pickering; W G Kramer; S Culbert; L S Frankel; S Kohl
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

Review 8.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

9.  Indications, interpretation and applications of antibiotic assays.

Authors:  E Yourassowsky
Journal:  Infection       Date:  1978       Impact factor: 3.553

Review 10.  Therapeutic drug monitoring of aminoglycosides in neonates.

Authors:  Daniël J Touw; Elsbeth M Westerman; Arwen J Sprij
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.